Norbrook Laboratories Ltd., based in the U.K., has achieved a milestone with the U.S. Food and Drug Administration (FDA) by gaining approval for Felanorm, the first generic methimazole oral solution for treating hyperthyroidism in cats. This approval marks a significant development in veterinary medicine, providing veterinarians with an alternative treatment option to the previously approved brand name drug, Felimazole Coated Tablets, which has been on the market since May 2009.
Felanorm contains the same active ingredient, methimazole, ensuring efficacy comparable to the brand name product. It is available exclusively through veterinary prescriptions and is supplied in 30 mL or 100 mL bottles, accompanied by a 1 mL dosing syringe.
According to the FDA, ongoing veterinary supervision is crucial due to the progressive nature of hyperthyroidism in cats, necessitating careful monitoring to adjust dosage as needed over time.
This approval not only expands treatment options for veterinarians managing feline hyperthyroidism but also underscores the importance of continued innovation in veterinary pharmaceuticals to enhance animal health care.
